New drug PQ203 enters human testing for Hard-to-Treat cancers
Disease control
Recruiting now
This early-stage trial tests the safety and best dose of a new drug called PQ203 in people with advanced solid tumors, including triple-negative breast cancer. About 80 participants whose cancer has progressed after standard treatments will receive the drug. The goal is to find a…
Phase: PHASE1 • Sponsor: ProteinQure Inc. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC